Table 3.
Estimated HER2A patient population size based on HER2A prevalence in 5391 non-breast tumors from TCGA
| Cancer | HER2A percentage | Estimated number of new cases in USA, 2015 | Estimated number of new HER2A cases |
|---|---|---|---|
| Breast carcinoma | 12.3% (106/864) | 234190 | 28805 |
| Stomach adenocarcinoma | 8.9% (24/271) | 24590 | 2189 |
| Bladder carcinoma | 4.2% (7/168) | 74000 | 3083 |
| Cervical squamous cell carcinoma and uterine carcinosarcoma | 4.1% (7/172) | 12900 | 529 |
| Uterine corpus endometrioid carcinoma | 3.4% (12/355) | 54870 | 1866 |
| Ovarian serous cystadenocarcinoma | 2.7% (11/401) | 21290 | 575 |
| Colon adenocarcinoma | 2.5% (5/203) | 93090 | 2327 |
| Lung adenocarcinoma and squamous cell carcinoma | 2.4% (21/884) | 221200 | 5309 |
| Head and neck squamous cell carcinoma | 2.3% (9/384) | 45780 | 1053 |
| Kidney renal papillary cell carcinoma | 1.3% (2/151) | N/A | N/A |
| Total across non-BC with HER2 amplification (11 cancers) | 3.3% (98/2989) | 16931 | |
| Total across all non-BC (23 cancers) | 1.8% (98/5391) |
Estimate of the number of new, annual human epidermal growth factor receptor 2 (HER2) amplified (HER2A) cancer cases in the USA, based on cancer figures from the American Cancer Society [50] and prevalence of HER2A in The Cancer Genome Atlas (TCGA). BC breast cancer, N/A not available